Abstract
Prostate cancer patients with inherited BRCA2 mutations have a survival disadvantage. However, it is unknown whether progression is associated with BRCA2 protein expression in diagnostic prostate cancer tissue, among men without inherited mutations. We conducted a nested case-control study within the Swedish Watchful Waiting cohort. The case group included all 71 patients who died from prostate cancer within 5 years from diagnosis and controls were all patients (n = 165) who lived at least 7 years after diagnosis. Tissue microarrays were stained using antibodies for C- and N-terminal domains of the BRCA2 protein. Location (nuclear, cytoplasmic and membranous) and magnitude (intensity and percentage) of expression were assessed. Logistic regression models produced odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, year of diagnosis and Gleason score. Positive BRCA2 staining at the cell membrane was associated with reduced risk of death within 5 years (N-terminal: OR = 0.47, 95% CI = 0.21-1.04, P = 0.06; C-terminal: OR = 0.41, 95% CI = 0.18-0.91, P = 0.03) and low Gleason scores (P = 0.006). Positive cytoplasmic C-terminal staining was associated with higher Gleason scores and increased lethality (OR = 3.61, 95%...Continue Reading
References
Jan 1, 1985·Statistics in Medicine·J Cuzick
Oct 1, 1985·Statistics in Medicine
Sep 2, 1998·International Journal of Cancer. Journal International Du Cancer·S M EdwardsR A Eeles
Aug 5, 1999·Journal of the National Cancer Institute·UNKNOWN Breast Cancer Linkage Consortium
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·B H SpainI M Verma
Mar 10, 2001·Molecular Cell·M E MoynahanM Jasin
Jul 12, 2001·Proceedings of the National Academy of Sciences of the United States of America·F XiaS N Powell
Apr 4, 2002·Human Molecular Genetics·Madhuri WarrenAlan Ashworth
Jul 13, 2002·Journal of Medical Genetics·H TuliniusJ E Eyfjord
Jun 3, 2005·Cancer Research·Xin-xia TianQingshen Gao
Jun 15, 2007·Journal of the National Cancer Institute·Laufey TryggvadóttirHrafn Tulinius
Nov 7, 2007·European Urology·Joost L Boormans, Fritz H Schröder
Jan 3, 2008·Cancer Science·Loredana MoroMargherita Greco
May 29, 2008·Journal of the National Cancer Institute·Sunita R SetlurMark A Rubin
Aug 28, 2009·Cancer Science·Takayoshi NiwaAkira Nakanishi
Jan 9, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Elena López-KnowlesSandra A O'Toole
Aug 26, 2010·British Journal of Cancer·S M EdwardsUNKNOWN UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology
Feb 2, 2011·The Journal of Cell Biology·Elisabeth D CoeneDavid J Vaux
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn L PenneyLorelei A Mucci
Sep 29, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Sabina DavidssonJennifer R Rider
Sep 10, 2013·Nature Structural & Molecular Biology·Anand D JeyasekharanAshok R Venkitaraman
Citations
Nov 28, 2018·Melanoma Research·Helena C SarubiLuiz De Marco
May 29, 2020·Pathology International·Georgi DzaparidzeAve Minajeva
Jul 6, 2017·Scientific Reports·Cathleen NientiedtStefan Duensing
Feb 11, 2021·Cancers·Konrad SopylloTuomas Mirtti